GSK (LON:GSK) Insider Wendy Becker Purchases 411 Shares

GSK plc (LON:GSK) insider Wendy Becker purchased 411 shares of the stock in a transaction on Friday, March 20th. The shares were bought at an average cost of GBX 1,963 per share, for a total transaction of £8,067.93.

Wendy Becker also recently made the following trade(s):

• On Friday, February 20th, Wendy Becker bought 3,334 shares of GSK stock. The stock was purchased at an average cost of GBX 2,219 per share, with a total value of £73,981.46.

GSK Price Performance

Shares of GSK opened at GBX 1,939 on Tuesday. The company has a market cap of £77.78 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 1.24 and a beta of 0.32. GSK plc has a 1-year low of GBX 1,242.50 and a 1-year high of GBX 2,282. The company’s fifty day simple moving average is GBX 2,026.08 and its 200 day simple moving average is GBX 1,820.75. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 108.20.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. On average, research analysts forecast that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

GSK has been the subject of several recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a research note on Wednesday, January 7th. Citigroup boosted their price target on GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research report on Monday, February 9th. UBS Group restated a “neutral” rating and issued a GBX 1,940 price objective on shares of GSK in a research note on Friday, January 23rd. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research note on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of GBX 1,917.86.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Senior insiders bought stock this week, signaling confidence from management: Jonathan Symonds purchased 5,000 shares at GBX 1,951 (~£97,550), Wendy Becker bought 411 shares at GBX 1,963 (~£8,068) and Anne Beal bought 196 shares (reported at GBX 5,179) — insider buying often suggests executives view the shares as undervalued.
• Positive Sentiment: GSK expanded its buyback program and increased treasury holdings, repurchasing 560,000 ordinary shares on 20 March (via BNP), which reduces float and supports EPS. Article Title
• Positive Sentiment: Regulatory progress: GSK’s lung cancer treatment received orphan drug designation in Japan, which can enable regulatory incentives, market exclusivity and a faster development path in that market. Article Title
• Neutral Sentiment: GSK admitted 96,525 new ordinary shares to trading under employee share plans — standard issuance for employee compensation; modest dilution but typical and usually neutral for near-term valuation. Article Title

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.